Founded in 2001 in Ghent, Belgium, Ablynx [Euronext Brussels: ABLX] is a
biopharmaceutical company focused on the discovery and development of
Nanobodies(R), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious and life-threatening human
The Company currently has over 180 employees. Ablynx completed a
successful IPO on Euronext Brussels [ABLX] on 7 November 2007.
Ablynx is developing a portfolio of Nanobody(R)-based therapeutic
programmes in a number of major disease areas, including inflammation,
thrombosis, oncology and Alzheimer's disease. Nanobodies(R) have been
generated against more than 100 different disease targets.
Efficacy data has been obtained in 20 in vivo models for Nanobodies(R)
against a range of different targets. Its lead programme, ALX-0081, a novel
anti-thrombotic is in a multi-dose Phase 1b study in patients. ALX-0681,
also a novel anti-thrombotic, is in advanced preclinical development.